Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zalutumumab plus best supportive care in non-curable squamous cell carcinoma of the head and neck after platinum failure
2008-000582-39Phase 2Completed
- Sponsor
- Genmab
- Start
- Jun 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zalutumumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Genmab. Primary endpoint: Overall survival. Started Jun 2008; status: completed.
02
Drugs
zalutumumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2008-000582-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000582-39.